Skip to main content
Premium Trial:

Request an Annual Quote

The Mouse Version

Some cancer patients are paying for their own mouse avatars on which to test possible drug therapies, the Associated Press reports.

"What I'm doing is personalized cancer treatment. It's the wave of the future," breast cancer patient Eileen Youtie tells the AP. "Part of this is trying to eliminate chemos that are not going to work on me. I don't want to waste time taking them and poison my body."

By grafting a portion of their tumor into lab mice, patients like Youtie hope to learn what drugs will best target their particular cancer. For some patients, the AP notes that mouse avatar testing can reveal that a tumor appears to be sensitive to a drug that isn't typically used to treat that cancer type.

Still, the AP notes that such testing is experimental and may not provide more information than gene tests or better outcomes than standard therapies. Mouse avatar testing, it adds, can cost upwards of $10,000 and isn't typically covered by insurance.

"I do see promise, but it's very time-consuming, it's very expensive," says Oklahoma Medical Research Foundation's Alana Welm. "For the average patient, standard care is going to be the way to go."


The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.